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1. Introduction 
Abnormal uterine bleeding is one of the most common reasons for women to seek for care. 
Dysfunctional uterine bleeding describes the spectrum of abnormal bleeding patterns in the 
abscence of a medical illness or pelvic pathology. It is responsible for about half of the 
women with abnormal uterine bleeding in reproductive age (Ewenstein, 1996). It mainly 
presents as menorrhagia, hence, the term generally refers to heavy, prolonged and frequent 
bleeding of uterine origin which is not due to any recognisable cause (Farrell, 2004). It is a 
debiliating disorder both medically and socially. In addition, it is the commonest cause of 
iron deficinecy in the developed world and of chronic illness in the developing world (Royal 
College of Obstetrics and Gynaecology [RCOG], 1998). The number of menses experienced 
by women in their lifetimes increased as a result of the reduction of family size leading to 
shorter periods of childbearing and lactational amenorrhoea. As a consequence, abnormal 
menstruation is especially a problem of the twentieth century (Farquhar & Brown, 2009). 
The prevelance of abnormal uterine bleeding in reproductive age group ranges from 9% to 
30% (Coulter et al.,1991). One in 20 women aged 30-49 in the UK consult their General 
Practitioner each year with menorrhagia, and it accounts for 12% of all gynaecology referrals 
(Vessey t al., 1992). 
Dysfunctional uterine bleeding is a diagnosis of exclusion. Menstrual history and physical 
examination are the mainstay of evaluation of cases. Laboratory tests, imaging studies and 
histologic examinations may be indicated, as well. Its management is complicated and 
variable according to the case. Although hysterectomy was the first option in the 1960s, 
medical treatment and less invasive surgical procedures have evolved recently. The aim of 
this chapter is to discuss the diagnostic steps and new treatment modalities of dysfunctional 
uterine bleeding based on a review of the literature. 
2. Definition of normal and abnormal uterine bleeding 
The usual duration of menstrual flow is 2-7 days with an interval of 21-35 days. The average 
volume of blood loss is between 30-80 ml. The traditional definitions of abnormal menstrual 
bleeding are: 
- Menorrhagia: Menstrual bleeding with excessive flow or duration. Intervals are regular.  
- Metrorrhagia: Irregular menstrual bleeding. 
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- Menometrorrhagia: Menstrual bleeding with excessive flow or duration. Intervals are 
irregular. 
- Intermenstrual  bleeding: Variable amounts of bleeding between normal regular 
menstrual periods. 
- Polymenorrhea: Menstrual bleeding with intervals of less than 21 days. 
- Oligomenorrhea: Menstrual bleeding with intervals of greater than 35 days. 
- Heavy menstrual bleeding is both menorrhagia and menometrorrhagia, and refers to 
the menstrual blood loss of higher than 80 ml per month.  
3. Measurement of menstrual blood loss 
Although heavy menstrual bleeding is  defined as  menstrual blood loss higher than 80 mL, 
up to 50% of women complaining of heavy menstrual bleeding have an objective blood loss 
lower than this level (Gannon et al., 1996). The assessment of menstrual blood loss is a 
complicated issue. The duration of menses and the number of sanitary pads worn do not 
correspond to the woman’s actual blood loss (Chimbira et al., 1980; Haynes et al., 1977), as 
the number of tampons worn reflects personal hygiene more than menstrual blood loss 
(Fraser et al., 1984).  For this reason, many techniques have been investigated for a long 
time, however, none of the objective methods are practical enough for clinical use. 
3.1 Direct measurement by using the alkaline hematin test 
The alkaline hematin test is an objective way of assessing menstrual blood loss by extracting 
hemoglobin from used sanitary pads, and converting it to hematin which is than measured 
spectrophotometrically (Hallberg & Nillson, 1964; Shaw et al., 1972). In many studies it was 
shown to be the accurate and simple method of measuring menstrual blood loss (Cheyne & 
Shepherd, 1970; Van Eijkeren et al., 1986; Vasilenko et al., 1988; Jannsen et al, 1995; 
Pendergrass et al, 1984). However, this is an impractical method that is rarely used outside 
of a research setting as it demands collecting the used feminine hygiene products (O’Flynn 
N & Britten, 2000; Chapple et al., 2001; Wyatt et al., 2001). 
3.2 Indirect measurement by using Pictorial Blood Loss Assessment Charts (PBAC) 
As the alkaline hematin technique was not appropriate for routine clinical use, a pictorial 
blood loss assessment chart was developed (Higham et al., 1990). In this method women 
assess the degree of staining of their used sanitary pads or tampons, and assign a numerical 
score. When this score was compared with the objective menstrual blood loss 
measurements, a sensitivity of 86% and a specificity of 89% were achieved with a PBAC 
score of ˃100 being positive (Higham et al., 1990). Recently it has been shown that a PBAC 
score of ˃150 for diagnosing menstrual blood loss ˃80 ml provided best precision and 
accuracy (Zakherah et al, 2011). It is accepted as a simple and accurate method of assessing 
blood loss that can be used in clinical practice (Zakherah et al., 2011; Barr et al., 1999). 
However, there are some studies questioning the discriminatory power as a diagnostic test 
(Deeny & Davis, 1994; Reid et al., 2000). As most of the studies ignored the extraneous blood 
loss, that is, blood not collected on feminine hygiene products, in one study participants 
were instructed to mark down the loss each time they changed their napkin or tampon 
(Wyatt et al., 2001).  The authors concluded that some women also lose a significantly large 
amount of extraneous blood,  which cannot be assessed by the alkaline hematin method.  
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3.3 Self-assessment measures 
The symptoms that may signify heavy menstrual bleeding include (Farrell, 2004): 
- an unusual increase in blood loss 
- more than 7 days of bleeding 
- bleeding or flooding not contained within pads or tampons (particularly if wearing the 
largest size) 
- clots larger than 3 cm.   
 
As the first two methods are impractical, measuring menstrual blood loss is not 
recommended except for research settings. Heavy menstrual bleeding is accepted as 
excessive menstrual loss which interferes with the woman’s physical, emotional and social 
quality of life. Whether menstrual blood loss is a problem, is advised to be determined not 
by measuring blood loss but by the women herself (National Collaborating Centre for 
Women’s and Children’s Health, 2007). 
There are many studies that compare the clinical parameters with objective menstrual blood 
volume. While some of them were unable to show a correlation between subjective 
assessment of menstrual blood loss and actual blood volume (Chimbira et al., 1980), the 
others revealed some correlation between menstrual blood volume and duration of menses, 
as well as clot size, ferritin level and frequency of pad change (Snowden & Christian, 1983; 
Higham & Shaw, 1999; Warner et al., 2004) . 
4. Pathogenesis of dysfunctional uterine bleeding 
4.1 Mechanism of normal menstruation 
The seat of normal menstrual bleeding is located in the upper two-thirds of the endometrial 
mucosa. It is characterized by tissue necrosis, disruption of microvasculature, migratory 
leukocytes, and platelet/fibrin thrombi in microvessels  (Ferenczy, 2003). Menstruation is 
initiated by the enzymatic degradation of the endometrium as a result of estrogen-
progesterone withdrawal. In the first half of the secretory phase of the menstrual cycle, acid 
phosphatase, and other potent lytic enzymes are confined to lysosomes. The release of these 
enzymes is inhibited by progesterone which stabilizes the lysosomal membranes. During 
the second half of the secretory phase, due to the withdrawal of estradiol and progesterone, 
the enzymes are released into the cytoplasmic substance and intercellular space. In the 
vascular endothelium lytic-enzyme release leads to platelet deposition, release of 
prostaglandins, vascular thrombosis, extravasation of red blood cells, and tissue necrosis 
(Ferenczy, 2003). In addition, the withdrawal of progesterone up-regulates key 
inflammatory mediators. Among the stimulated agents the ǂ-chemokine CXCL8 (neutrophil 
chemotactic factor, IL-8) and the ǃ-chemokine CCL-2 (monocyte chemotactic peptide-1, 
MCP-1), as well as the inducible enzyme, COX-2 are responsible for the synthesis of 
prostaglandins (Jabbour et al., 2006). 
Immediately before and during menstruation, there is the induction of the expression, 
secretion, and activation of  matrix metalloproteinases which have the capacity to degrade 
all of the components of extracellular matrix (Salamonsen, 2003). Progesterone inhibits 
endometrial metalloproteinase expression, an action mediated by transforming growth 
factor-ǃ (Brunnel et al., 1995). As a result of progesterone withdrawal, metalloproteinase 
secretion and activation are increased, followed by dissolution of the extracellular matrix  
(Irwin et al., 1996). The enzymatic degradation of endometrium extends to the deepest 
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extent of functional layer, where the rupture of basal arterioles contribute to bleeding that 
caused by the dissolution of the surface membrane. A cleavage plane develops at the 
junction  of the loose, vascular, edematous stroma with the basal layer. Desquamation 
begins in the fundus and gradually extends towards the isthmus (Speroff & Fritz, 2005).  
Immediately after separation of the functional layer of the endometrium, endometrial 
regeneration and vessel growth are initiated by the influence of estradiol. TGF-ǂ, EGF, and 
platelet derived growth factor (PDGF) are mitogens for epithelial cells that origin from the 
basal layer (Chan et al., 2004). Vascular endothelial growth factor (VEGF) together with FGF 
and PDGF are known to stimulate angiogenesis in the endometrium (Weston & Rogers, 
2000).  Early in menstruation the hemostasis is provided by platelet and fibrin plug 
formation. However, the cessation of menstrual bleeding depends on vasoconstriction of the 
denuded spiral arterioles in the basal layer and possibly of the radial arteries of superficial 
myometrium, an action that is promoted by endothelins and prostaglandins in the 
menstrual endometrium (Ferenczy, 2003).  
In summary, normal menstruation is a process initiated by the release of lysosomal enzymes 
which leads to the shedding of the functional layer of endometrium, and  terminated by the 
restructuring of the endometrium, and the vasoconstriction of the spiral arterioles and the 
radial arteries. 
4.2 Mechanism of dysfunctional uterine bleeding 
There are two types of dysfunctional uterine bleeding; ovulatory (10%) and anovulatory 
(90%). In ovulatory cycles the menstrual pattern is uniform, regular and heavy but of 
normal duration. On the contrary, in anovulatory cycles the pattern is variable, irregular 
and the duration may be longer (Speroff & Fritz, 2005). Ovulatory dysfunctional uterine 
bleeding is the major pattern in 30s, whereas anovulatory dysfunctional uterine bleeding is 
more likely to occur at the extremes of reproductive years and in women who have 
polycystic ovarian syndrome. 
In ovulatory dysfunctional uterine bleeding, generally circulating ovarian hormone levels 
are normal and endometrial histology shows changes identical to women without 
dysfunctional uterine bleeding.  Therefore, the major proposed mechanism of ovulatory 
dysfunctional uterine bleeding is impaired hemostatic mechanisms. A shift in the ratio of 
endometrial vasoconstrictor (PGF2ǂ) to vasodilator (PGE2), and an increase in total 
endometrial prostaglandins have been demonstrated in ovulatory dysfunctional uterine 
bleeding patients (Ferenzcy, 2003). Platelet and plug formation are poor due to prolonged 
vasodilation .  In addition, a potent vasodilator parathyroid hormone- related protein and 
high proteolytic lysosomal enzyme activity are increased in women with ovulatory 
dysfunctional uterine bleeding (Casey & Mac Donald, 1996). As a result, in ovulatory 
dysfunctional uterine bleeding, treatment with  prostaglandin synthetase inhibitors are 
more effective than hormonal treatment. However, there are rare hormonal conditions that 
cause abnormal uterine bleeding in ovulatory cycles. The most common one is midcycle 
bleeding due to abrupt fall in estrogen levels just before the ovulation which is called as 
‘estrogen withdrawal bleeding’. Another one is the luteal phase defect which is 
characterized by spotting before the menstruation because of insufficient progesterone 
secretion, and known as ‘progesterone withdrawal bleeding’. 
Anovulatory dysfunctional bleeding occurs as a result of endometrial response to abnormal 
levels of steroid hormones. As normal menstruation results from estrogen-progesterone 
withdrawal, hyperestrogenic or hyperprogestogenic  states end with anovulatory bleeding. 
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While estrogen is the principal hormone which is effective on the endometrial glands and 
vasculature, progesterone mainly affects the stroma. In normal menstruation cycle, estrogen 
and progesterone stimulus is balanced leading to stable endometrial epithelium, stroma, 
and microvasculature. Random breakdown is avoided, and endometrial shedding occurs 
uniformly throughout the endometrial cavity.  Prolonged hyperestrogenism unopposed by 
progesterone, leads to proliferative endometrium and hyperplasia with a poor stromal 
matrix (Ferenzcy, 2003). The bleeding caused by focal stromal breakdown is called ‘estrogen 
breakthrough bleeding’. Endometrial shedding is  irregular, and not universal. There is 
constantly changing patchwork of small repairs instead of organized and well structured 
remodeling.  In persistent proliferative endometrium, spiral arterioles are often suppressed 
and venous capillaries are dilated and increased in number (Ferenczy, 2003). Also, the 
sensitivity of abnormal vasculature in hyperestrogenic endometrium is suspected to be 
greater to vasodilation by prostaglandins  than to their vasoconstrictor counterparts (Smith 
et al., 1982). In addition, a potent vasoconstrictor, angiotensin-2 is decreased in endometrial 
hyperplasia (Li & Ahmed, 1996). Anovulatory dysfunctional uterine bleeding is initiated by 
an increase in vascular density with abnormal structural abnormalities leading to rupture or 
degradation of the microvascular system (Ferenzcy, 2003). As tissue loss involves the 
superficial endometrium only focally, vasoconstriction of basal and radial arteries does not 
occur and this causes abnormalities in hemostasis. This is the mechanism of bleeding in 
chronic anovulation. The amount and duration of bleeding can vary according to the 
amount and duration of unopposed estrogen exposure (Speroff & Fritz, 2005). Low level 
chronic estrogen stimulation typically results in intermittent spotting, whereas sustained 
high level estrogen exposure commonly results in acute episodes of profuse bleeding.  
Anovulatory dysfunctional uterine bleeding due to hyperprogestogenism, known as 
‘progesterone breakthrough bleeding’ manifests in continuous progestin or low-dose oral 
contraceptive users. Endometrial histology is chiefly influenced by progesterone and ranges 
from severe atrophy with or without stromal decidualization to mixed 
proliferative/secretory patterns  according to the duration and amount of progesterone 
exposure (Ferenczy, 2003). As the progesterone/estrogen ratio increases, secretory-type 
atrophy becomes prominent with a gland-stroma ratio largely in favour of the stroma. 
Histologically there  is a decrease in the number and turtuoisity of spiral arterioles and 
many of the subepithelial microvessels are dilated and lined by a very thin endothelial cell 
layer (Hickey et al., 2000). Since the basement membrane is poorly formed or absent, and 
there are gaps between endothelial cells,  pools of extravasated red blood cells are often seen 
(Hourihan et al., 1986). These structural alterations and vascular fragility lead to breakdown 
and bleeding. 
5. Differential diagnosis 
Dysfunctional uterine bleeding is a diagnosis of exclusion. In half of women with 
menorrhagia there is no organic cause (Pitkin, 2007). In the first place, the aim is to exclude 
the structural and histological abnormalities and dysfunctional uterine bleeding is 
diagnosed when all of the organic causes are ruled out. Table 1 shows the list of etiologic 
factors leading to abnormal  uterine bleeding. 
Pregnancy is the most important etiologic factor that should be excluded primarily. Ectopic 
pregnancy, abortion, placental abnormalities and gestational trophoblastic diseases are the 
major causes of abnormal uterine bleeding. 
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Structural abnormalities of uterus such as leimyoma, polyp or endometrial hyperplasia 
manifest as heavy menstrual bleeding. In addition, abnormal uterine bleeding is the most 
frequent symptom of women with  cervical and endometrial malignancies. Adenomyosis is 
characterized with heavy painful bleeding with dyspareunia. Furthermore, women with  
chronic endometritis and cervicitis can experience irregular bleeding. A woman who has 
multiple partners, and complains for the symptoms of heavy menstrual bleeding and 
dysmenorrhea should be evaluated for pelvic inflammatory disease (PID).    
Endocrine abnormalities account for an important proportion of abnormal uterine bleeding. 
Both hypotyroidism and hypertyroidism are associated with abnormal uterine bleeding. 
Hyperprolactinemia  and diabetes mellitus are associated with anovulation. Policytic ovary 
syndrome (PCOS) is the most common cause of anovulation with a prevelance of 5% to 8% 
(Azziz et al., 2004). The diagnostic criteria for PCOS include at least two of the following 
(The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004): 
1. Menstrual irregularity due to oligo- or anovulation. 
2. Signs of androgen excess, either on physical examination (eg, hirsutism, acne) or 
laboratory testing (eg, elevated testosterone) 
3. Evidence of polycystic ovaries by ultrasound.  
Conditions that should be ruled out include congenital adrenal hyperplasia (manifested by 
an elevated early morning 17-hydroxyprogesterone), androgen-secreting tumors 
(manifested by a serum testosterone ˃200 ng/dl or dehydroepiandrosterone sulfate ˃800 
µg/dl), and hyperprolactinemia  (Ely et al., 2006). 
Coagulopathies and anticoagulant  drug intake should be taken into account during the 
evaluation of heavy menstrual bleeding. Von Willebrand disease is a common cause of 
pubertal menorrhagia. Besides, a systemic review of 11 studies from Europe and the USA 
showed an overall prevalence of 13% in reproductive years (Shankar et al., 2004). 
Trombocytopenia and leukemia also may cause abnormal uterine bleeding.  
6. Diagnostic evaluation 
Detailed menstrual history can provide most of the information needed to differentiate 
anovulatory bleeding from the other causes of abnormal uterine bleeding.  Intermenstrual 
intervals, volume and duration of bleeding, previous menstrual patterns, associated 
symptoms and temporal associations, such as postcoital or postpartum, should be asked. 
Medications, especially exogenous hormones and systemic diseases, such as renal or liver 
dysfunction, should be considered during the evaluation. Physical examination is necessary 
to determine the origin of bleeding and to exclude vaginal and cervical pathologies. Vaginal 
discharge,  uterus size and contour, and uterine  tenderness should be noted.  
Imaging studies may be needed for differential diagnosis. Transvaginal ultrasound is the 
first-line diagnostic tool for identifying structural abnormalities in dysfunctional uterine 
bleeding (National Collaborating Centre for Women’s and Children’s Health, 2007). It is 
performed for the diagnosis of fibroid, endometrial polyp, intrauterine and ectopic 
pregnancy. Saline infusion sonography is a noninvasive imaging study which has a high 
sensitivity in diagnosis of endometrial polyp and submucous myom. Hysteroscopy should 
be used as a diagnostic tool only when ultrasound results are inconclusive, for example in 
order to determine the exact location of a fibroid or the exact nature of the abnormality 
(National Collaborating Centre for Women’s and Children’s Health, 2007). In addition, CT 
and MRI can be used for the evaluation of pelvic masses and malignancies. 
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Pregnancy-related bleeding Ectopic pregnancy 
Abortion 
Gestational trophoblastic diseases 
Placenta previa 
Ablatio placenta 
Anatomic causes Fibroids 
Endometrial and endocervical polyps 
Endometrial hyperplasia 
Adenomyosis 
Infectious causes Endometritis 
Cervicitis 
Neoplasia Endometrial cancer 
Cervical cancer 
Endocrine  causes Hypothyroidism and hyperthyroidism 
Hyperprolactinemia 
Adrenal gland dysfunction 
Hypothalamic and pituitary dysfunction 
Estrogen producing tumors 
Polycytic ovary syndrome 
Diabetes mellitus 
Hematologic causes Coagulopathies:  
von Willebrand disease 
Thrombocytopenia 
Leukemia 
Exogenous hormones and the 






Systemic illnesses Chronic renal failure 





Dysfunctional uterine bleeding Ovulatory 
Anovulatory  
Table 1. Causes of abnormal uterine bleeding 
Complete blood count should be performed in all cases to determine the level of anemia and 
to estimate the amount of bleeding. ǃ-hCG is necessary in order to exclude pregnancy. 
Women with family history or additional bleeding symptoms,  adolescents with acute 
bleeding, and those who have abnormal bleeding since menarche should be investigated for 
hematologic diseases with platelet count, prothrombin time and partial thromboplastin 
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time. Also in chronic liver disease and alcoholism coagulation parameters should be 
considered.  Tyroid stimulating hormone (TSH) should be screened early in the evaluation 
(Ely et al., 2006). Prolactin level is evaluated in the presence of galactorrhea or 
oligomenorrhea.  Follicule stimulating hormone (FSH) and estradiol levels may be assessed 
in perimenopausal women. FSH, LH, testosterone, 17-OH progesterone and DHEAS are 
performed if polycystic ovary syndrome is suspected.  Liver and renal function tests are not 
recommended during the first evaluation, but should be assessed according to the medical 
history of patient. 
Pap-smear should be a part of clinical examination. Endometrial sampling is mandatory in 
the evaluation of women older than 35 years of age (ACOG, 2001). Also, it should be 
performed to the younger women with the history of chronic anovulation in order to 
exclude endometrial carcinoma and hyperplasia. In addition, any cervical mass should be 
investigated with a biopsy. Table 2 summarizes the diagnostic evaluation of abnormal 
uterine bleeding. 
 
History Intermenstrual interval 
Volume of bleeding (number of sanitary pads or 
tampons per day) 
Duration of bleeding 
Associated symptoms (dysmenorrhea, hirsutism, 
galactorrhea, pelvic pain) 








Imaging studies Transvaginal ultrasonography 
Saline infusion sonography 
Hysteroscopy 
CT and MRI 
Laboratory tests Complete blood count 
Β-hCG 
Tyroid function tests 
Prolactin 
FSH, LH, estradiol 
Testosterone, 17–OH- P, DHEAS 
PT, APTT 
Renal and liver function tests 
Histologic examination Pap-smear 
Endometrial sampling 
Cervical biopsy 
Table 2. Summary of diagnostic evaluation of abnormal uterine bleeding. 
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7. Treatment of dysfunctional uterine bleeding 
Hysterectomy was the most commonly performed treatment for menorrhagia in the past. 
80% of the women treated for menorrhagia had no uterine abnormality and over a third of 
the women undergoing hysterectomies for heavy menstrual bleeding had a normal uterus 
removed (Gath et al., 1982; Clarke et al,. 1995). Today, in spite of the high patient satisfaction 
rate of hysterectomy, medical therapies or less invasive surgical procedures are preferred 
instead of hysterectomy in order to avoid its serious complications. Need for contraception, 
contraindications for treatment and patient choices are the factors influencing the selection 
of therapy. Iron supplements should be prescribed in addition to  any kind of therapy. Table 
3 shows a list of treatment modalities of dysfunctional uterine bleeding. 
 
1. Medical treatment 
 
I. Hormonal medications 
a. Progestogens 
b. Estrogen 
c. Oral contraceptives 
d. Danazol 
e. GnRH analogues 
 
II. Non-hormonal medications 
a.      Nonsteroidal anti-inflammatory drugs (NSAIDs) 
b. Tranexamic acid  
 
III. Levonorgestrel-releasing intrauterine system  
 




II. Endometrial resection and ablation 
a.       First generation techniques 
b.      Second generation techniques 
Table 3. Treatment of dysfunctional uterine bleeding 
7.1 Medical management 
Medical therapy is the first-line therapy in dysfunctional uterine bleeding. Cyclic 
progestogens are the most common prescribed drugs for dysfunctional uterine bleeding. 
Combined oral contraceptives and levonorgestrel intrauterine system provide additional 
contraceptive effect. Nonsteroidal anti-inflammatory drugs and tranexamic acid are 
medications that offer a simple therapy to be taken only during menses. Although danazol 
and gonadotropin-releasing hormone analogues are highly effective, they are not used 
frequently due to their side effects and high costs. They can be used for a short period in 
women waiting for surgery. Effective use of medical therapies reduces the number of 
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surgical procedures. A combination of two or more of these agents may be required to 
successfully control the abnormal uterine bleeding. 
7.1.1 Hormonal medications 
7.1.1.1 Progestogens 
Progestogens are the mainstay of the treatment of anovulatory bleeding. Progestogens 
account for 55% of the total prescribed drugs for menorrhagia and norethisterone is the 
most commonly prescribed progestogen in the UK (Coulter et al., 1995). In anovulatory 
women with menorrhagia,  progestin treatment control the bleeding coordinating regular 
uterine shedding. Progestogens have an anti-mitotic effect on the endometrium, because 
they stimulate 17ǃ-hydroxysteroid dehydrogenase and sulfotransferase activity, the 
enzymes that convert estradiol to estrone sulfate (Gurpide et al., 1976). They also inhibit 
estrogen’s induction of its own receptor and suppress estrogen-mediated transcription of 
oncogens (Kirkland et al., 1992). As a consequence of these effects, continuous progestogens 
induce endometrial atrophy, and prevent estrogen-stimulated endometrial proliferation 
(Hichey et al., 2007). 
Progestogens are administered in luteal phase from day 15 or 19 to day 26 in anovulatory 
cycles. In a comparison of 5 mg norethisteron three times daily with 10 mg 
medroxyprogesterone acetate three times daily for 14 days, no obvious difference was 
observed  between  these two progestogens (Fraser et al., 1990). Recently an increase in the 
duration and dosage has been investigated in patients with ovulatory dysfunctional uterine 
bleeding, and administration of oral progestogens from day 5 to day 26 of the cycle 
produced a significant reduction in bleeding (Lethaby et al., 2008).  The studies which 
compared luteal progestogens with the other medical therapies have revealed that oral 
progestogens were less effective in reducing menstrual blood loss when compared with 
tranexamic acid, danazol and progesterone-releasing intrauterine system, whereas there was 
no significant difference when compared with nonsteroidal anti-inflammatory drugs 
(Lethaby et al., 2008).  In addition, it is shown that progestogens were less effective than 
levonorgestrel-releasing intrauterine system, but had a lower incidence of intermenstrual 
bleeding and breast tenderness (Irvine et al., 1998). 
For emergency suppression of heavy menstrual bleeding norethisteron at least 15 mg per 
day, or medroxyprogesterone acetate at least 30 mg per day is prescribed until bleeding 
ceases and a maintenance dose should be continued until the woman has 3-4 weeks free of 
bleeding (Farrell, 2004). 
Fatigue, mood changes, weight gain, nausea, bloating, edema, headache, depression, loss of 
libido, irregular bleeding and atherogenic changes in the lipid profile can be associated with 
the prolonged use of high-dose progestogens (Lethaby et al., 2008). 
7.1.1.2 Estrogen 
Estrogen is mostly administered in acute and heavy bleeding when the endometrium is 
grossly denuded. Intravenous administration of 25 mg conjugated equine estrogens every 4 
hours until bleeding subsides or for 24 hours is very effective in reducing heavy bleeding 
(DeVore et al, 1982). In less severe cases high dose oral estrogen (1.25 mg conjugated 
estrogens or 2.0 mg micronized estradiol every 4-6 hours for 24 hours) can control bleeding 
(Speroff & Fritz, 2005). After the bleeding lightens the dose should be tapered to once a day 
for another 7-10 days. If the bleeding is lighter single daily dose of  1.25 mg conjugated 
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estrogen or 2 mg micronized estradiol for 7-10 days is enough to control bleeding (Speroff & 
Fritz, 2005). After the initial estrogen therapy a progestogen should be added and continued 
until the 21st day of therapy in order to generate a withdrawal bleeding. 
Due to chronic low level estrogen stimulation,  the endometrium becomes very thin and 
denuded resulting in intermittent spotting and staining. In these cases, progestin therapy 
cannot be used because progesterone affect only the endometrium stimulated by estrogen 
previously. Thus, estrogen therapy is preferred in women with a thin endometrium 
assessed by transvaginal ultrasound. Similarly, in progesterone breakthrough bleeding 
owing to depot forms of progestin therapy or low dose estrogen-progestin contraceptives, 
1.25 mg oral conjugated estrogen or 2 mg oral micronized estradiol is added to therapy for 
7-10 days. 
7.1.1.3 Oral contraceptives 
Oral contraceptives reduce the amount of bleeding by 40% in dysfunctional uterine bleeding 
(Fraser & McCarron, 1991). When taken in a cyclical fashion it induces regular shedding of a 
thinner endometrium and inhibits ovulation. Good cycle control together with the provision 
of contraception makes it more acceptable long term therapy for menorrhagia (Farquer & 
Brown, 2009). It is also a good option in cases of heavy bleeding when the endometrium 
thickness is uniformly increased. Although it contains both estrogen and progestin, the main 
action is performed by the progestin (Speroff & Fritz, 2005). One common oral contraceptive 
regimen for severe acute bleeding is one pill four times daily for four days followed by three 
times daily for three days, followed by twice daily for two days, followed by once daily for 
three weeks. Then after a break of one week, oral contraceptive is taken on a regular basis 
using three weeks on and one week off, for at least three months (Ely et al., 2006). 
In anovulatory cycles in order to prevent the recurrence of heavy bleeding, it should be 
administered daily throughout following cycles as a maintenance therapy. If there is any 
contraindication for oral contraceptive use, cyclic progestogens are chosen instead, however, 
they do not avoid pregnancy. The contraindications of oral contraceptives are; previous 
thromboembolic event or stroke, history of estrogen-dependent tumor, active liver disease, 
pregnancy, hypertriglyceridemia and smoking ˃ 15 cigarettes per day of women older than 
35 years (Ely et al., 2006). In addition, long-term use of oral contraceptives are not preferred 
by many women as a therapy of menorrhagia.  
7.1.1.4 Danazol 
Danazol is a drug chemically derived from testosterone. It reduces the menstrual blood loss 
because it inhibits ovulation, reduces estrogen level and causes endometrial atrophy 
(Beaumont et al., 2007). The standard dose is 200 mg/day, although the studies did not 
show any difference in effectiveness or frequency of adverse effects when compared with a 
lower dose of 100 mg/day (Chimbira et al., 1980) and  a reducing dose regimen (Higham & 
Shaw, 1993). Danazol is found to be more effective than progestogens, nonsteroidal anti-
inflammatory drugs and oral contraceptive pills, although it caused more severe side effects 
in comparison to progestogens and nonsteroidal anti-inflammatory drugs (Beaumont et al., 
2007). When the treatment is discontinued, the effects of danazol persist for two to three 
cycles before blood loss returns to pre-treatment levels (Chimbira et al., 1979). 
As it is derived from testosterone, it has  androgenic effects which may result in acne, 
seborrhoea, hirsutism, and hoarseness. Also, it may cause weight gain, nausea, tiredness, 
irritability, musculoskeletal pains, hot flushes, breast atrophy and benign hepatic adenomas 
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in case of its prolonged administration (Beaumont et al., 2007). Moreover, an additional 
contraceptive is required because of its teratogenic effect . 
7.1.1.5 GnRH analogues 
They have a limited role in the treatment of dysfunctional uterine bleeding, but can be used as 
pretreatment before endometrial ablation. The success of hysteroscopic procedure depends on 
complete endometrial destruction. The radius of a standard electrosurgical loop used for 
endometrial resection is about four mm and the dept of tissue destruction with Nd:YAG laser 
or a roller ball electrode is four to six mm (Goldrath, 1990; Duffy, 1992). The success rate 
increases if surgery is undertaken in the immediate post-menstrual phase or following the 
administration of hormonal agents which induce endometrial thinning or atrophy (Sowter, 
2002). GnRH analogues are the most common evaluated drugs in the studies. Danazol is also 
used for this purpose, but less frequently. The use of goserelin acetate (GnRH analogue) before 
hysteroscope shortens operating time, and reduces  intra-operative distension medium 
absorption (Donnez, 1997). Also it provides an ease of surgery and a higher rate of post-
operative amenorrhea after 12 months of surgery (Vilos, 1996; Sowter, 2002). However, in 
MISTLETOE study in over 10000 endometrial resections, the use of endometrial thinning 
agents was not associated with any reductions in complication rates (Overton, 1997). Also 
patient satisfaction is highly irrespective of the use of GnRH-analogues (Sowter, 2002). 
7.1.2 Non-hormonal medications 
7.1.2.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 
The endometrium of women with menorrhagia has been found to have higher levels of 
PGE2 and F2a when compared with normal menses (Willman et al., 1976). Also, the ratio of 
prostaglandin E2 to F2, and the ratio of prostaglandin I2 to thromboxane are elevated 
resulting in deranged hemostasis (Smith et al., 1981; Makarainen & Ylikorkala, 1986). 
Nonsteroidal anti-inflammatory drugs inhibiting prostaglandin synthesis by the enzyme 
cyclo-oxgenase, reduce the  menstrual blood loss approximately 20-40% and to a greater 
extent in those with excessive bleeding (Hall et al., 1987; Shaw et al, 1994).  
Mefenamic acid, naproxen, ibuprofen, flurbiprofen, meclofenamic acid, diclofenac, 
indomethacin and asetylsalicyclic acid are used for the treatment of heavy menstrual 
bleeding. There are no differences in clinical efficiency between individual prostaglandin 
inhibitors. However, there are some women who seem to respond well to one agent but less 
well to another (Lethaby et al, 2007). As a group, Nonsteroidal anti-inflammatory drugs are 
less effective than tranexamic acid, danazol and levonorgestrel releasing intrauterine 
system, whereas there was no significant difference in efficacy in comparison with oral 
luteal progestogen, ethamsylate, and oral contraceptive pill (Lethaby et al, 2007). 
The advantage of this treatment is the low incidence of side effects as the drug is used only 
during the bleeding period. Also,  it provides relief from dysmenorrhea which is often 
related to heavy menstrual bleeding. Side effects of nonsteroidal anti-inflammatory drugs 
include  headache and gastroinstestinal symptoms such as nausea, vomiting, diarrhea and 
dyspepsia. Contraindications  are gastrointestinal disorders such as ulcers, intolerance to 
nonsteroidal anti-inflammatory drugs, or asthma (Farrell, 2004). 
7.1.2.2 Tranexamic acid 
Tranexamic acid is an anti-fibrinolytic. Plasminogen activators, the enzymes that cause 
fibrinolysis, are found in higher levels in the endometrium of women with heavy menstrual 
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bleeding than those with normal menstrual bleeding (Gleeson, 1994). Thus, anti-fibrinolytic 
drugs are used in the treatment of menorrhagia. Tranexamic acid is more effective than 
either nonsteroidal anti-inflammatory drugs and oral luteal phase progestogens (Lethaby et 
al., 2000). Also the studies comparing tranexamic acid with oral progestogens for changes in 
quality of life showed that the former is more effective in improving flooding and leakage 
problems and sex life (Lethaby et al., 2000). It  is prescribed on only the heavy days of the 
menses, with a dose of 1 g 3-4 times daily (Farrell, 2004). However, in a study a dose of 2 
g/day is shown to be more effective than 10 mg twice-daily medroxyprogesterone acetate 
(Kriplani et al, 2006). Tranexamic acid may be considered as a first-line treatment for 
ovulatory dysfunctional uterine bleeding, especially for patients in whom hormonal 
treatment is either not recommended or not wanted (National Health Committee New 
Zealand, 1998; Wellington & Wagstaff, 2003). 
Although it is known to reduce the menstrual blood loss by 50% (Higham & Shaw,1991), 
tranexamic acid has not been used widely because of its possible side effects. Since it is an 
anti-fibrinolytic drug, it is suggested to be associated with thrombogenic disease. However, 
the studies were unable to show increased rates of thrombogenic disease with tranexamic 
acid administration in comparison to placebo (Rybo, 1991). The recent studies proved that 
tranexamic acid is an effective and safe form of medical therapy in women with 
menorrhagia without any serious adverse effects (Kriplani et al., 2006; Srinil  & Jaisamrarn, 
2005; Lukes et al., 2010). 
Eythamsylate is a drug used rarely in heavy menstrual bleeding. Even though it is not a true 
anti-fibrinolytic, it affects in a similar mechanism. It reduces capillary bleeding by correcting 
abnormal platelet function (Lethaby et al, 2000). 
7.1.3 Levonorgestrel-releasing intrauterine system 
Levonorgestrel-releasing intrauterine system has been developed primarily as a 
contraceptive device which does not suppress ovulation. It consists of a T-shaped 
intrauterine device sheated with a reservoir of levonorgestrel that is released at the rate of 20 
µg daily. This low level of hormone minimizes the systemic progestogenic effects, and 
patients are more likely to continue with this therapy than with cyclical progestogen 
therapy (Irvine et al., 1998). It prevents the endometrial proliferation and reduces both the 
duration and amount of bleeding (Silverberg et al., 1986). It is accepted as an alternative to 
surgery with a reduction in menstrual blood loss up to 90% (Milsom, 2007; Andersson et al., 
1994). It is more effective than the other medical therapies (Lethaby et al, 2005). A study 
comparing the efficacy of levonorgestrel-releasing intrauterine system to oral 
contraceptives, showed a more pronunced clinical benefit  with levonorgestrel-releasing 
intrauterine system therapy in terms of decreasing menstrual blood loss score after 6 months 
of treatment (Endricat et al., 2009). This is a more acceptable treatment than norethisterone 
taken for 21 days of the cycle for the women, and they are more satisfied with this therapy 
(Irvine et al., 1998). Levonorgestrel-releasing intrauterine system treatment has been 
compared to either transcervical resection of the endometrium or balloon ablation (Lethaby 
et al., 2005). Although there was a higher rate of successful treatment in those undergoing 
transcervical resection or balloon ablation in four trials, rates of satisfaction and change in 
quality of life were similar, but women with levonorgestrel-releasing intrauterine system 
had a greater incidence of progestogenic side effects within a year. In two studies, 82% and 
64% of women on a waiting list of hysterectomy cancelled their surgery after using 
levonorgestrel-releasing intrauterine system (Barrington & Bowen-Simpkins,  1997; 
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Lähteenmaki et al., 1998). Another study comparing levonorgestrel-releasing intrauterine 
system with hysterectomy, revealed that there was no significant difference in quality of life 
scores, but the former treatment had lower costs than the latter (Hurskainen  et al., 2001).  
Side effects are  ectopic pregnancy, expulsion of device and progestogenic effects such as 
bloating, weight gain and breast tenderness (Lethaby et al., 2005). Irregular bleeding and 
spotting are temporary and generally seen in the first three months. However, after 12 
months of therapy, there is a major reduction in blood loss up to 97%, thus, most of the 
women have a light bleeding and 20% of them have amenorrhea. As amenorrhea and 
altered bleeding patterns may be undesirable to some women (Chi, 1993), counselling before 
insertion is very important.  Relief from dysmenorrhea and reduced incidence of pelvic 
inflammatory disease due to the thickening of the utero-cervical mucus are additional 
advantages of levonorgestrel-releasing intrauterine system (Andersson et al., 1994). An 
increased incidence of transient ovarian cysts has been reported with levonorgestrel-
releasing intrauterine system use (Brache et al., 2002). 
Due to its high efficacy in reducing menstrual blood loss without disturbing fertility, this 
method offers a first-line therapy for dysfunctional uterine bleeding in women of any 
reproductive age who wish a contraceptive method and  accept hormonal drug use. 
7.2 Surgical treatment 
Surgical procedures are performed when medical therapy fails or there is an associated 
symptom such as pain. Also, some of the patients prefer surgery instead of long-term use of 
medications. These techniques should not be performed to women who wish to have further 
pregnancies.  These procedures include hysterectomy, endometrial resection and ablation. 
Dilatation and curettage is no longer accepted as a therapeutic treatment (National 
Collaborating Centre for Women’s and Children’s Health, 2007). 
All of the surgical procedures are  much more successful than oral medications (Cooper et 
al.,1997, Kupperman et al., 2004). In addition, the rate of satisfaction and overall quality of 
life were higher in women who had surgery (Marjoribanks et al., 2006). Also, when 
conservative surgery (endometrial resection and ablation) was compared with 
levonoregtrel-releasing intrauterine system, conservative surgery was more effective in 
controlling bleeding at one year, however, patients satisfaction rates and quality of life were 
not different between these two groups (Marjoribanks et al., 2006). 
7.2.1 Hysterectomy 
Hysterectomy has been traditionally regarded as the definitive surgical treatment for 
menorrhagia and menstrual disorders have been the leading indication of hysterectomy 
(Farquhar & Steiner, 2002). There are three types of hysterectomy; laparoscopically assisted, 
vaginal and abdominal. The laparoscopically assisted hysterectomy by a competent and 
experienced operator is the most appropriate technique with less morbidity (Farrell, 2004). 
Hysterectomy is associated with 100% success in treating heavy menstrual bleeding and a 
high patient satisfaction up to 95% (Marjoribanks et al., 2006), but have complications and 
rarely operative mortality.  For this reason, hysterectomy should not be as a fist-line 
treatment (National Callobarating Centre for Women’s and Children’s Health, 2007). It 
should be only considered when other treatment options have failed or there is a wish for 
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7.2.2 Endometrial resection and ablation 
These procedures involve the destruction of the full thickness of endometrium together with 
the superficial myometrium including the deep basal glands (Lethaby et al., 2009).  First 
generation techniques utilize hysteroscope, and require general or regional anesthesia, 
surgical skill and hospital admission (Marjoribanks et al., 2006). By contrast, second 
generation techniques do not use hysteroscope, do not require surgical skill and can be done 
as one day or outpatient surgery with a local anaesthetic (Jack et al., 2005). Compared to 
hysterectomy, endometrial destruction techniques have a shorter operation time and 
hospital stay, quicker recovery, and fewer postoperative complications (Marjoribanks et al., 
2006).  On the other hand, hysterectomy is more successful in improvement in heavy 
menstrual bleeding and higher satisfaction rates compared to endometrial ablation (Lethaby 
et al., 1999). Repeat surgery due to the failure of the initial treatment, was more likely after 
endometrial ablation than hysterectomy (3 to 18% versus 1%) (Lethaby et al., 1999).  The  
initial cost of endometrial destruction is significantly lower than hysterectomy, but, since re-
treatment is often necesssary, the cost difference narrows over time (Lethaby et al, 1999). 
Although hysterectomy is  much more successful than these procedures, there is now 
evidence that it is used less frequently in clinical practice (Reid, 2007). 
Endometrial resection and ablation should be offered to the women who do not wish further 
childbearing. However, unlike hysterectomy, pregnancy after endometrial ablation is 
possible although it is not often (Kdous et al., 2008). Premenopausal women should have a 
post-operative contraception method, because serious complications such as spontaneous 
abortion, prematurity, uterine rupture, and placenta adhesion complications  in the 
pregnancies after endometrial ablation have been reported (Laberge, 2008; Kuzel et al., 2010; 
Yin , 2010). 
7.2.2.1 First generation techniques 
The first effective ablation of the endometrium under hysteroscopic vision for the treatment 
of dysfunctional uterine bleeding was performed using laser photovapourisation (Goldrath 
et al., 1981). A few years later rollerball ablation with electrosurgical equipment (Lin et al,. 
1988; Vaincaillie, 1989) and transcervical resection of the endometrium (TCRE) with 
resectoscope (DeCherney et al., 1983, 1987) began to be performed. These procedures have 
the advantage of diagnosis polyps as they directly visualize the endometrial cavity. Overall 
complication rate has been reported as 4.4% and ablation either by laser or rollerball were 
safer than endometrial resection (Overton et al., 1997). The risk of immediate hemorrhage 
was three times greater and the risk of uterine perforation was four times greater with 
resection than ablation. In a multicentre study, of the 1866 women followed up for at least 
one year after laser endometrial ablation, 56% developed complete amenorrhea, 38% 
reported continuing but satisfactorily reduced menstruation, and 7% patients failed to 
improve with the first treatment. Overall, 93% had a satisfactory response to laser ablation 
and only 1.8% required subsequent hysterectomy (Erian, 1994). It is reported that 
amenorrhea is best attained when complete preoperative atrophy is achieved, by either 
depot goserelin (GnRH analogue) or danazol, although goserelin appears to be more 
effective and better tolerated than danazol (Alford & Hopkins, 1996; Garry et al., 1996; 
Fraser et al., 1996). 
7.2.2.2 Second generation techniques 
Second generation procedures except hydrothermal ablation and endometrial laser 
intrauterine thermal therapy are performed without direct visualization through a 
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hysteroscope (Lethaby et al., 2009). These procedures include cryoablation (Pitroff et al., 
1993), hot saline solution irrigation (Baggish et al.,1995), diode laser hyperthermy (heating) 
(Donnez et al.,1996), microwave ablation (Sharp et al., 1995), a heated balloon system (Singer 
et al.,1994) and photodynamic therapy (intrauterine light delivery) (Fehr et al.,1995). A 
meta-analysis of 21 studies with 3395 premenopausal women showed that when these 
procedures were compared with first generation techniques, there were no significant 
difference in reducing menstrual blood loss and the rate of re-intervention and satisfaction 
(Lethaby et al., 2009). Second generation techniques were easier to perform with shorter 
surgery times using local anaesthesia. While intra and postoperative complications such as 
fluid overload, perforation, cervical lacerations and hematometra, were more common with 
first generation, other types of complications, nausea, vomiting, and uterine cramping and 
pain, were more common with second generation techniques (Lethaby et al, 2009). These 
methods are complex which have the potential of mechanical breakdown. Considerable 
experience in intrauterine cavity assessment and manipulation is required for safely use of 
these devices. 
8. Conclusion 
Dysfunctional uterine bleeding is a common, debiliating condition.  There is no practical 
method of measuring the amount of bleeding, and the assessment of menstrual blood loss is 
based on the complains of woman. While anovulatory dysfunctional uterine bleeding is 
commonly seen at both ends of the reproductive years because of hypothalamic immaturity 
and perimenopausal changes, ovulatory type is majorly seen in the 30s and its mechanism is 
less well understood. Physical examination and diagnostic tests are performed with the aim 
of exclusion of pregnancy and organic diseases. There are many different types of therapy, 
and the selection is mainly depends on the wishes and conditions of the patient. The 
treatment of anovulatory dysfunctional uterine bleeding is simple as it is usually treated 
effectively by replacing the missing component, progesterone, in the luteal phase. However,  
the treatment of ovulatory dysfunctional uterine bleeding is more complex. Nonsteroidal 
anti-inflammatory drugs or tranexamic acid is the current first-line treatment for those that 
wish to conceive or do not accept hormonal treatment. Also, they are preferred while 
investigations and definite treatment are being organized. Combined oral contraceptives, 
progestogens from days 5 to 26 of the menstrual cycle, or levonorgestrel-releasing 
intrauterine system are acceptable for the other women, although the latter seems to be best 
option when long term use is anticipated. On the other hand, danazol and GnRH analogues 
are not used routinely. Surgical treatment is considered when bleeding is a severe impact on 
a woman’s quality of life and there is no wish of further conception. Although hysterectomy 
was the most commonly performed procedure in the past, the recently evolved conservative 
surgeries are preferred today. Second generation endometrial ablation procedures are going 
to become more prevalent in the future. However, more studies with longer duration of 
follow-up are needed to clarify the long-term benefits. 
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